Circulating cathepsin K and cystatin C in patients with cancer related bone disease: Clinical and therapeutic implications

Biomedicine and Pharmacotherapy

Volumn 62, Issue 2, 2008, Pages 130-135

  Tumminello, Francesca M ^a   Flandina, Carla ^a   Crescimanno, Marilena ^a   Leto, Gaetano ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Bone metastasis cathepsin K; Cystatin C

Indexed keywords

CATHEPSIN K; CYSTATIN C; ZOLEDRONIC ACID;

ARTICLE; BLOOD DONOR; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG POTENCY; ENZYME ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CATHEPSINS; CYSTATINS; DIPHOSPHONATES; DISEASE PROGRESSION; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 38949145299     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.07.001     Document Type: Article

References (35)

1. Goto T., Yamaza T., and Tanaka T. Cathepsins in the osteoclasts. J Electron Microsc 52 6 (2003) 551-558
2. Delaisse J.M., Andersen T.L., Engsig M.T., Henriksen K., Troen T., and Blavier L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech 61 6 (2003) 504-513
3. Mandelin J., Hukkanen M., Li T.-F., Korhonen M., Liljeström M., Sillat T., et al. Human osteoblast produce cathepsin K. Bone 38 (2006) 769-777
4. Keppler D. Towards novel anticancer strategies based on cystatin function. Cancer Lett 235 (2006) 159-176
5. Yamaza T., Tsuji Y., Goto T., Kido M.A., Nishijima K., Moroi R., et al. Comparison in localization between cystatin C and cathepsin K in osteoclasts and other cells in mouse tibia epiphysis by immunolight and immunoelectron microscopy. Bone 29 1 (2001) 42-53
6. Brage M., Lie A., Ransjö M., Kasprzykowski F., Kasprzykowska R., Abrahamson M., et al. Osteoclastogenesis is decreased by cysteine proteinase inhibitors. Bone 34 (2004) 412-424
7. Sokol J., and Schiemann W.P. Cystatin C antagonizes transforming growth factor β signalling in normal and cancer cells. Mol Cancer Res 2 (2004) 183-195
8. Gelb B.D., Shi G.P., Chapman H.A., and Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273 (1996) 1236-1238
9. Yasuda Y., Kaleta J., and Brömme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 57 (2005) 973-993
10. Ma G.F., Ali A., Verzijl N., Hanemaaijer R., TeKoppele J., Konttinen Y.T., et al. Increased collagen degradation around loosened total hip replacement implants. Arthritis Rheum 54 9 (2006) 2928-2933
11. Hansen T., Petrow P.K., Gaumann A., Keyszer G.M., Otto M., Kirkpatrick C.J., et al. Expression of cysteine proteinases cathepsins B and K, and cysteine proteinase inhibitor cystatin C in giant cell tumor of tendon sheath. Mod Pathol 14 (2001) 318-324
12. Skoumal M., Haberhauer G., Kolarz G., Hawa G., and Woloszuczuk W. Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction. Arthritis Res Ther 7 (2005) R65-R70 10.1186/ar1461
13. Holzer G., Noske H., Lang T., Holzer L., and Willinger U. Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures. J Lab Clin Med 146 (2005) 13-17
14. Meier C., Meinhardt U., Greenfield J.R., De Winter J., Nguyen T.V., Dunstan C.R., et al. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clin Lab 52 (2006) 1-10
15. Söderström M., Ekfors T., Böhling T., Aho A., Hannu T.A., and Vuorio E. Cysteine proteinases in chondrosarcomas. Matrix Biol 19 (2001) 717-725
16. Lindeman J.H.N., Hanemaaijer R., Mulder A., Dijkstra S., Szuhai K., Bromme D., et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 165 (2004) 593-600
17. Littlewood-Evans A.J., Bilbe G., Bowler W.B., Farley D., Wlodarski B., Kokubo T., et al. The osteoclast associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57 23 (1997) 5386-5390
18. Lu Y., Keller E., Daj J., Escara-Wilke J., Ghobrial I., Yao Z., et al. Role of cathepsin K in prostate cancer skeletal metastasis. Proc Am Assoc Cancer Res 46 (2005) [abstract 2905]
19. Roodman G.D. Mechanism of bone metastasis. N Eng J Med 350 (2004) 1655-1664
20. Santini D., Fratto M.E., Vincenzi B., Galluzzo S., and Tonini G. Zoledronic acid in the management of metastatic bone disease. Expert Opin Biol Ther 6 12 (2006) 1333-1348
21. Leto G., Badalamenti G., Arcara C., Crescimanno M., Flandina C., Tumminello F.M., et al. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. Anticancer Res 26 I (2006) 23-26
22. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ 79 4 (2001) 373-374
23. Hanely J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29-36
24. Hanley J.A., and McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148 (1983) 839-843
25. Brubaker K.D., Vessella R.L., True L.D., Thomas R., and Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 18 2 (2003) 222-230
26. Yano M., Hirai K., Naito Z., Yokoyama M., Ishiwata T., Shiraki Y., et al. Expression of cathepsin B and cystatin C in human breast cancer. Surg Today 31 5 (2001) 385-389
27. Jiborn T., Abrahamson M., Gadaleanu V., Lundwall A., and Bjartell A. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation. BJU Int 98 (2006) 189-196
28. Kos J., Stabuc B., Cimerman N., and Brünner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 44 12 (1998) 2556-2557
29. Mulaomerović A., Halibašić A., Čičkušić E., Zavanšnik-Bergant T., Begić L., and Kos J. Cystatin C as a potential marker of relapse in patients with non-Hodgkin B-cell lymphoma. Cancer Lett 248 (2007) 192-197
30. Kos J., Werle T., Lah T., and Brünner N. Cysteine proteinases and their inhibitors in extracellular fluids: marker for diagnosis and prognosis in cancer. Int J Biol Markers 15 (2000) 84-89
31. Sun Q. Growth stimulation of 3T3 fibroblasts by cystatin. Exp Cell Res 180 (1989) 150-160
32. Tavera C., Leung-Tack D., Prevot D., Gensac M.C., Martinez J., Fulcrand A., et al. Cystatin C secretion by rat glomerular mesengial cells: autocrine loop for in vitro growth promoting activity. Biochem Biophys Res Comm 182 (1992) 1082-1088
33. Garnero P., Ferreras M., Karsdal M.A., Nicamhlaoibh R., Risteli J., Borel O., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18 5 (2003) 859-867
34. Karsdal M.A., Henriksen K., Sorensen M.G., Gram J., Schaller S., Dziegiel M.H., et al. Acidification of the osteoclast resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166 (2005) 467-476
35. Fromigué O., and Body J.J. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 25 (2002) 539-546